CSL to pay up to $1.6 bln to develop rare disease drug; shares rise
Covered in this story
Call it yourself
No calls on $CSL yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Carlisle Companies →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.